Order Article Reprints

Kınıkoğlu O, Odabas H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S, et al. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina. 2024; 60(6):951. https://doi.org/10.3390/medicina60060951

Kınıkoğlu, Oğuzcan, Hatice Odabas, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yıldırım, Hamit Bal, Tuğba Kaya, Salih Tünbekici, and et al. 2024. "Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer" Medicina 60, no. 6: 951. https://doi.org/10.3390/medicina60060951

Kınıkoğlu, O., Odabas, H., Altıntaş, Y. E., Yıldız, A., Çakan, B., Akdağ, G., Yıldırım, S., Bal, H., Kaya, T., Tünbekici, S., Işık, D., Başoğlu, T., Yıldırım, M. E., & Turan, N. (2024). Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina, 60(6), 951. https://doi.org/10.3390/medicina60060951